(S,R,S)-BBO-11818

Overview

(S,R,S)-BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS ), non-covalent pan- KRAS inhibitor ( IC 50 =28-120 nM). (S,R,S)-BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the KRAS:RAF1 interaction by inducing conformational changes, and blocks the MAPK signaling pathway. (S,R,S)-BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis , but also drives tumor regression in xenograft models. (S,R,S)-BBO-11818 produces synergistic effects when combined with Cetuximab ( HY-P9905 ), anti- PD-1 antibody or PI3Kα inhibitor. (S,R,S)-BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer , non-small cell lung cancer and colorectal cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > ERK | Products > Signaling Pathways > Ras | Products > Signaling Pathways > Phosphatase

Product Information

• Catalog No.: HY-181420
• CAS No.: 3029184-80-0
• Molecular Formula: C34H33F6N7O3S
• Molecular Weight: 733.73
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source